Publication | Open Access

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Hematological MalignancyOncologyMedicineDay 1Advanced Solid TumoursPharmacotherapyMetronomic ChemotherapyCancer TreatmentPharmacologyRadiation OncologyTumor MicroenvironmentCancer ResearchIntravenous Tzt-1027RadiologyHealth Sciences